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Globally, adolescents aged 10 - 19 years are the only age group 
in which AIDS-related deaths are increasing, and AIDS is now 
the leading cause of adolescent death in Africa.[1] Combination 
antiretroviral therapy (cART) increases long-term survival and 
wellbeing of people living with HIV,[2] but requires diligent lifetime 
adherence of ~87 - 95%.[3] However, cART has also been associated 
with toxicities in clinical trials. Low adherence rates are common 
among HIV-positive adolescents and rates have been shown to 
worsen over time,[4,5] but more research is needed to understand 
what drives adolescent non-adherence to cART, particularly in sub-
Saharan Africa. Side-effects of cART are important both with regard 
to quality of life and as potential predictors of non-adherence. In 
clinical practice, symptoms associated with cART use and symptoms 
of opportunistic infections in HIV or other illnesses can easily be 
confused. Symptoms commonly listed in the literature as side-
effects of cART include skin rash, fatigue/tiredness, nausea/vomiting, 
diarrhoea/stomach ache, insomnia/bad dreams, headache, fever, dry 
mouth and dizziness.[6-9] Evidence on cART-related symptoms among 
adolescents is very limited, particularly in sub-Saharan Africa, where 
a >90-fold increase in cART access has occurred in the past decade. [10] 
Most studies reporting cART-related outcomes focus on adults or 
younger children (<14 years) or include very few children.[4,7,11-17]
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Background. Studies investigating symptoms associated with combination antiretroviral therapy (cART) use among adolescents in 
resource-limited settings are rare beyond clinical trials. Identifying adolescents at risk of non-adherence is imperative for HIV/AIDS 
programming and controlling the epidemic in this key population.
Objective. To examine which cART regimens were associated with reports of multiple symptoms and past-week non-adherence in a large 
community-traced sample of HIV-positive adolescents in South Africa (SA).
Methods. A total of 1 175 HIV-positive ART-experienced adolescents aged 10 - 19 years attending 53 health facilities in the Eastern 
Cape Province, SA, were interviewed in 2014 - 2015. Ninety percent (n=1 059) were included in the study. Adolescents who reported no 
medication use and those with unclear or missing data were excluded from further analysis, resulting in a sample for analysis of n=501. 
Outcomes were reports of multiple symptoms (three or more symptoms in the past 6 months) and past-week ART non-adherence (<95% 
correct doses in the past week). Multivariable logistic regression analyses controlled for sociodemographic and HIV-related covariates in 
Stata 13/IC.
Results. Of the adolescents included, 54.3% were female. The median age was 14 (interquartile range 12 - 16) years, and 66.5% were 
vertically infected. The prevalence of multiple symptoms was 59.7% (95% confidence interval (CI) 55.3 - 63.9). Independent of covariates, 
stavudine (d4T)-containing cART regimens and the fixed-dose combination of tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV) 
were associated with more reports of multiple symptoms (adjusted odds ratio (aOR) 3.38; 95% CI 1.19 - 9.60 and aOR 2.67; 95% CI 1.21 - 
5.88, respectively). Lopinavir/ritonavir (LPV/r)-containing regimens were associated with fewer reports of multiple symptoms (aOR 0.47; 
95% CI 0.21 - 1.04). For EFV-based regimens, adolescents on d4T + lamivudine (3TC) + EFV were more likely to report multiple symptoms 
than those on TDF + FTC + EFV or those on abacavir (ABC) + 3TC + EFV (aOR 3.26; 95% CI 1.01 - 10.52, aOR 2.86; 95% CI 1.35 - 6.05 
and aOR 1.08; 95% CI 0.64 - 1.82, respectively). However, only TDF + FTC + EFV cART was associated with lower levels of non-adherence 
among participants (aOR 0.44; 95% CI 0.21 - 0.93).
Conclusions. Rates of multiple symptoms among HIV-positive ART-experienced adolescents were high. d4T-containing regimens and 
TDF + FTC + EFV were associated with more reports of multiple symptoms, whereas LPV/r-containing regimens were associated with 
fewer reports. However, adolescents on TDF + FTC + EFV were the most adherent subgroup. These findings support the World Health 
Organization-recommended discontinuation of d4T use, but also underscore the dilemma faced by clinicians when choosing between low-
toxicity regimens and those that promote ART adherence, particularly among HIV-positive adolescents.
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In younger children, observational studies and randomised 
controlled trials (RCTs) comparing nucleoside/nucleotide reverse 
transcriptase inhibitor (NRTI)-based and non-nucleotide reverse 
transcriptase inhibitor (NNRTI)-based regimens have found no 
major differences in toxicity profiles,[15,17-19] including in children 
with prior nevirapine (NVP) exposure.[20] In Uganda, 23% of 
children aged <18 years reported mild to moderate symptoms, 
and in Rwanda, 33% of children aged <15 reported cART-related 
symptoms, 9% of whom required treatment modification. However, 
these studies did not specify which regimens/regimen components 
were likely to be associated with the reported symptoms.[8,21] Studies 
in high-income countries have shown zidovudine (AZT)-based 
regimens to be safer than stavudine (d4T)-based regimens,[9] and 
lopinavir/ritonavir (LPV/r)-based regimens to be safe and effective 
in HIV-infected children.[22,23] Studies in adults report cough, fever, 
peripheral neuropathy, skin rash, pruritus, diarrhoea and dizziness 
to be common among participants on AZT- and d4T-based cART, 
with higher prevalences in participants on AZT-based regimens than 
in those on d4T-based regimens.[14,24] RCTs and systematic reviews in 
adults in high-income countries have also shown efavirenz (EFV)-
based regimens to be associated with more symptoms than non-
EFV-based regimens.[7,25]
To date, no study has examined associations between cART 
regimens and reports of multiple symptoms among HIV-positive 
adolescents. Clinical trials of specific medications (which often 
exclude children and adolescents aged <18 years) may underestimate 
treatment-associated symptoms because they are conducted in strictly 
controlled settings and follow participants for only a limited period.
Objective
To examine which cART regimens were associated with reports 
of multiple symptoms and past-week non-adherence in a large 
community-traced sample of HIV-positive 10 - 19-year-old adoles-
cents in South Africa (SA). For the purposes of the study, multiple 
symptoms were defined as reports of three or more symptoms in the 
past 6 months and non-adherence as <95% of prescribed doses taken 
correctly in the past week.
Methods
This was a cross-sectional study conducted with HIV-positive 
adolescents aged 10 - 19 years, resident in a mixed urban, periurban 
and rural health district of Amathole (area 21 117 km2, total 
population 880 790),[26,27] Eastern Cape – SA’s poorest province, with 
an antenatal HIV prevalence of 29.1% (95% confidence interval (CI) 
27.3 - 30.9).[28] ART-providing public health facilities that reported 
four or more adolescents on treatment in the study area were 
selected (N=53). All ART-experienced adolescents in these healthcare 
facilities were identified (N=1 175 eligible) and then followed up in 
their homes (community tracing) to enable participant inclusion 
regardless of clinic attendance status (active or lost to follow-up). 
Reasons for non-participation were as follows: caregiver or adolescent 
refused (4.1%), severe cognitive delays (0.9%), untraceable (3.7%) 
and not interviewed for safety reasons (1.2%). Of the eligible sample, 
90.1% (n=1 059) of ART-experienced adolescents were interviewed 
alongside 467 community controls, 10 - 19-year-old adolescents who 
were either living in the same home or a neighbouring home.
Research tools were translated and back-translated from English 
into Xhosa and piloted with 25 HIV-positive adolescents. Adolescents 
used their preferred language. Interviewers were trained in conducting 
research with HIV-affected adolescents. To prevent stigmatisation of 
participants and unintended disclosure, the study was presented 
within communities and organisations as investigating adolescent 
health service needs. Conﬁdentiality was maintained, except when 
participants requested assistance or were at risk of signiﬁcant harm. 
In cases of self-reported abuse, rape or risk of signiﬁcant harm, 
adolescents were referred to child protection and health services 
with follow-up support where needed. Voluntary informed consent 
was obtained from all adolescents aged ≥18 years, and assent was 
obtained from those aged <18, with their caregivers providing 
consent. There were no incentives provided, but participants received 
a pack containing a snack, a toothbrush, toothpaste, and a certiﬁcate 
of participation.
Ethics approval
Ethical clearance was obtained from the relevant academic institutions 
(the universities of Oxford (ref. no. SSD/CUREC2/12-21) and Cape 
Town (ref. no. CSSR 2013/4)), governmental organisations (the 
Eastern Cape departments of Health and Basic Education), and 
ethical review boards of participating health facilities.
Measures
The adolescents’ knowledge of their own HIV status was determined 
from clinic records and healthcare worker and primary caregiver 
reports. Owing to discrepancies between these sources, it was 
imperative to check that adolescents understood their HIV status to 
prevent unintentional disclosure through research.[29,30] Adolescents 
were asked about whether they knew what their illness was, whether 
they had ever been tested for HIV and whether they knew what their 
medication was for. Those who reported not knowing their status 
were asked about ‘illness’ and ‘medication’ instead of ‘HIV’ and ‘ART’ 
throughout the study.
Symptoms were assessed using the verbal symptoms scale.[31] 
Adolescents were asked about a range of symptoms and how 
frequently (never, sometimes, often) they had experienced them in 
the past 6 months. Anxiety was assessed using a pro-rated version of 
the revised children’s manifest anxiety scale (RCMAS).[32] 
Treatment information was obtained by asking adolescents to 
state the names of their current medication where known, or say 
‘I don’t know’ if unknown. Participant responses were entered as 
free text in the dataset by the interviewer. Given the unreliability of 
clinical records in resource-limited settings, a photograph of their 
current medication was taken by the interviewer where possible. 
ART and other medication variables were generated from textual 
and photographic medication data and coded using the 2015 SA 
national ART guidelines,[6] corroborated by the 2015 World Health 
Organization (WHO)[33] and National Institutes of Health ART 
guidelines,[34] and through consultations with paediatric ART expert 
clinicians and nurse practitioners. Individual ART variables were 
then combined into specific cART regimens and broader groups of 
NRTI-, NNRTI- and protease inhibitor (PI)-containing regimens 
in accordance with the 2015 SA national ART guidelines,[6] expert 
clinician guidance and precedent studies.[15,17,25] For example, if the 
adolescents’ textual or photographic responses included abacavir 
(ABC), they were coded as 1 on a dummy variable for ABC-based 
regimens. If the responses included multiple medicines, these were 
recoded in individual dummy variables. Where brand names were 
used, for example Erige for EFV, Kaletra or Aluvia for ritonavir-
boosted LPV and Atripla for the fixed-dose combination TDF + 
emtricitabine (FTC) + EFV, expert clinicians were consulted to assign 
standard medicine codes. Combination ART variables were generated 
in accordance with the 2015 SA national ART guidelines[6] and the 
2015 WHO guidelines.[33] For example, adolescents were coded on 
the ABC + lamivudine (3TC) +EFV combination regimen if they 
had three dummy variables from their textual and/or photographic 
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responses for ABC, 3TC and EFV. Higher-level ART variables were 
generated as follows: participants were positively coded for NNRTI-
based regimens if they were on a regimen containing either EFV or 
NVP, for NRTI-based regimens if they were on a regimen containing 
either ABC or tenofovir (TDF) or d4T or AZT, and for PI-based 
regimens if they were on a regimen containing LPV/r, darunavir-
ritonavir (DRV/r), atazanavir (ATV), raltegravir or DRV/retravirine.
Past-week ART non-adherence was defined as <95% correct 
doses in the past week[35] and assessed by adolescent self-report[36,37] 
based on items from the standardised Patient Medication Adherence 
Questionnaire[38] combined with measures developed in Botswana. [39] 
Adolescent past-week ART non-adherence in this study has already 
been validated using patient file viral load (VL) data and self-
reported opportunistic infections.[5,40]
Potential covariates included sociodemographic, health and 
wellbeing/HIV-related and healthcare-related factors. Socio-
demographics of adolescent age, sex, language, urban/rural 
residence and formal/informal housing were measured using items 
adapted from the 2011 South African census.[41] Poverty, defined 
in this study as lacking all the eight socially perceived necessities 
for children, was measured using an index of household assets 
corroborated by 80% of the population in a nationally representative 
survey.[42] Food insecurity was measured using items from the SA 
National Food Consumption Survey[43] and was defined as spending 
2 or more days in the past week without sufficient food. HIV-
related factors included positive status knowledge, VL, CD4+ count, 
opportunistic infections and mode of infection (vertical/horizontal). 
Recent CD4+ and VL data were extracted from patient files and the 
Tier.Net database after obtaining approval from participants and 
administrators at participating clinics. Suboptimal immunity was 
defined as a CD4+ count <500 cells/µL, based on the WHO 2013 
ART treatment guidelines.[44] Recent treatment failure was defined 
as VL >1 000 copies/mL.[19] Opportunistic infections, defined as 
reporting sores on the body or face, tuberculosis (TB) or mouth 
ulcers in the past 6 months, were assessed using a verbal symptom 
scale. Using data from similar studies in SA, adolescents were classed 
as vertically infected if they had started ART before age 12 years or if 
they had been on treatment for >5 years.[45] Overall health (excellent/
not excellent) and medication cofactors of age at ART initiation, 
daily pill burden, medication frequency, antibiotics/TB medication 
and past-year ART stock-outs were recorded through adolescent self-
report. Time on treatment was calculated as the difference between 
adolescent age and age at ART initiation. Healthcare cofactors linked 
with non-adherence included clinic transport problems (at least 
one negative experience related to transport), clinic staff problems 
(>3  negative clinic staff-related experiences), and clinic facility 
problems (>3 negative facility- or accessibility-related experiences).
Data analysis
Of the included HIV-positive sample (n=1 059), adolescents with 
unclear or missing information (31.5%) and those who stated no 
current medication use, including defaulters (21.2%), were excluded 
from subsequent analyses (n=558, 53.0%), generating a final sample 
for analysis of n=501. Adolescent ART self-reports were validated 
using patient file data at participating clinics and the Tier.net 
database, using a subsample (n=194, 38.7%) of participants.
Analyses were conducted in five stages in SPSS version 22 (IBM, 
USA) and Stata version 13.0/IC (StataCorp, USA). First, to check for 
potential differences between the included and excluded participants, 
the two groups were compared on known characteristics. Subgroup 
differences in medians and proportions were assessed using the 
median command and a series of χ2 tests, respectively (Table 1). 
Second, we described the baseline sociodemographic, health and 
wellbeing characteristics of the included sample (Table 2). Third, a 
literature-based strategy was used to determine common medication 
symptoms.[6,46,47] We assessed the distribution of symptoms between 
HIV-positive adolescents and community controls (apparently 
HIV-negative adolescents) and eliminated symptoms that were not 
differentially distributed between the two groups (headache, fever 
and backache; results available on request). The final ten symptoms 
that were analysed as potentially ART-associated were ear problems, 
skin rash, diarrhoea, nausea/vomiting, stomach problems, dizziness, 
problems sleeping/bad dreams, tiredness, weight loss and clinical 
anxiety (scores >9 on a pro-rated RCMAS). Our study aimed to 
identify severely affected adolescents (a clinically important group), 
so the major outcome – multiple symptoms – was computed as 
reports of ≥3 symptoms in the past 6 months. 
Fourth, associations of cART regimens with multiple symptoms 
were tested in multivariate logistic regressions using a subsample of 
468 (93.4%) HIV-positive ART-experienced adolescents who had 
complete data for all the included variables. Analyses controlled 
for potential confounders of age, gender, rural residence, overall 
Table 1. Comparison of known baseline characteristics of included and excluded adolescents in the study (N=1 059)
Characteristic
Included
(N=501)
Excluded
(N=558) χ2 p-value‡
Age (yr), median (IQR)† 14 (12 - 16) 13 (11 - 16) 16.133 <0.001*
Girls, n (%) 272 (54.3) 311 (55.7) 0.222 0.637
Rural, n (%) 98 (19.4) 129 (23.3) 2.161 0.142
Informal housing, n (%) 88 (17.6) 111 (19.9) 0.937 0.333
Food insecurity, n (%) 62 (12.4) 91 (16.3) 3.348 0.067*
Past-month poor health, n (%) 211 (42.1) 223 (40.0) 0.505 0.477
Perinatally infected, n (%) 333 (66.5) 375 (67.2) 0.065 0.799
Time on treatment (years), median (IQR)† 5 (2 - 9) 5 (2 - 10) 0.018 0.892
Pill burden (≥5/day), n (%) 260 (51.9) 280 (52.0) 0.002 0.962
Daily dosing frequency ≥2, n (%) 240 (47.9) 246 (45.7) 0.495 0.482
≥3 self-reported symptoms, n (%) 299 (59.7) 349 (62.7) 0.985 0.321
Past-week non-adherence, n (%) 149 (29.7) 236 (42.3) 17.989 <0.001*
Any opportunistic infections, n (%) 298 (59.5) 333 (59.7) 0.004 0.948
IQR = interquartile range.
*Significant at p<0.1.
†Continuous variables were skewed and could not be transformed successfully, so medians (IQR) are presented.
‡p-values are from median tests for continous variables and from χ2 tests for categorical variables.
968       November 2017, Vol. 107, No. 11
RESEARCH
health status, food insecurity, lacking all the eight basic necessities, 
antibiotics/TB medication, pill burden (≥5), daily dosing frequency 
(≥2), past-week non-adherence, CD4+ count (<500 cells/µL), recent 
treatment failure (VL >1 000 copies/mL), opportunistic infections, 
ART stock-outs, vertical infection and time on treatment. Separate 
models (Tables 3, 4, 5 and 6) were run as follows: (i) comparing 
NRTI-based regimens (ABC-containing v. AZT-containing v. TDF-
containing v. d4T-containing regimens); (ii) comparing TDF + FTC + 
EFV v. other EFV-containing regimens; (iii) comparing NNRTI-
based v. PI-based (EFV-containing v. LPV/r-containing regimens); 
and (iv) comparing EFV-based regimens (D4T + 3TC + EFV v. 
TDF + FTC + EFV v. ABC + 3TC + EFV). In the latter model, ABC + 
Table 2. Characteristics of adolescents included in the study (N=501)
Characteristic n (%) 95% CI Median (IQR)
Sociodemographic variables
Overall age (yr)* 14 (12 - 16)
10 - 14 282 (56.3) 51.9 - 60.6
15 - 19 219 (43.7) 39.4 - 48.1
Xhosa language 488 (97.4) 95.6 - 98.5
Girls 272 (54.3) 49.9 - 58.6
Rural residence 98 (19.6) 16.3 - 23.3
Informal housing 88 (17.6) 14.5 - 21.2
Poverty (lacked access to basic necessities) 338 (67.5) 63.2 - 71.4
Food insecurity 62 (12.4) 9.8 - 15.6
Orphanhood (any) 303 (60.5) 56.1 - 64.7
Health and wellbeing variables
Excellent health (no) 290 (57.9) 53.5 - 62.2
Knows HIV status (yes) 427 (85.2) 81.8 - 88.1
Perinatally infected 333 (66.5) 62.2 - 70.5
Self-reported symptoms 
≥3 self-reported symptoms 299 (59.7) 55.3 - 63.9
Shingles/skin rash 223 (44.5) 40.2 - 48.9
Diarrhoea 219 (43.7) 39.4 - 48.1
Nausea/vomiting 217 (43.3) 39.0 - 47.7
Tires easily 211 (42.1) 37.9 - 46.5
Stomach problems 202 (40.3) 36.1 - 44.7
Dizziness 167 (33.3) 29.3 - 37.6
Ear problems 160 (31.9) 28.0 - 36.2
Bad dreams/insomnia 149 (29.7) 25.9 - 33.9
Weight loss 131 (26.2) 22.5 - 30.2
Anxiety (above clinical cut-off) 12 (2.4) 1.4 - 4.2
Medication variables
Number of ARVs, median (IQR)* 3 (1 - 3)
One ARV 180 (35.9) 31.8 - 40.2
≥2 ARVs 321 (64.1) 59.8 - 68.2
≥5 pills/day 260 (51.9) 47.5 - 56.3
Daily dosing frequency ≥2 240 (47.9) 43.5 - 52.3
Antibiotics, including TB medication 70 (14.0) 11.2 - 17.4
EFV-based regimens 354 (70.7) 66.5 - 74.5
LPV/r-based regimens 85 (17.0) 13.9 - 20.5
3TC-based regimens 322 (64.3) 41.6 - 48.6
ABC-based regimens 231 (46.1) 41.8 - 50.5
TDF-based regimens 143 (28.5) 24.8 - 32.7
AZT-based regimens 51 (10.2) 7.8 - 13.2
D4T-based regimens 32 (6.4) 4.5 - 8.9
NVP-based regimens 3 (0.6) 0.2 - 1.9
3TC monotherapy 38 (7.6) 5.6 - 10.3
TDF + FTC + EFV 116 (23.2) 19.7 - 27.1
ABC + 3TC + EFV 165 (32.9) 28.9 - 37.2
Past week non-adherence 149 (29.7) 25.9 - 33.9
Time on treatment (yr)* 5 (2 - 10)
CI = confidence interval; IQR = interquartile range; ARV/s = antiretroviral/s; TB = tuberculosis; EFV = efavirenz; LPV/r = lopinavir/ritonavir; 3TC = lamivudine; ABC = abacavir;  
TDF = tenofovir; AZT = zidovudine; d4T = stavudine; FTC = emtricitabine.
*Continuous variables were skewed and could not be transformed successfully, so medians (IQR) are presented.
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3TC + EFV, being the largest of the three EFV-based regimens, was 
selected as the reference category. Covariates were simultaneously 
added to each model. Predicted probabilities of reporting multiple 
symptoms were computed for all major cART regimens in marginal-
effects models, adjusted for all covariates held at their mean values. 
Associations between cART regimens and individual symptoms were 
also explored and presented (Table 7). Low-frequency ART regimens 
(n<20 adolescents) were excluded from analyses.
Fifth, we assessed which cART regimens (only those significant 
in stage 4 above) were associated with adolescent self-reported non-
adherence (past week), adjusted for several covariates including 
multiple symptoms (Table 8).
Table 3. Comparing NRTI-based cART regimens, all potential covariates simultaneously added to the model (N=468)
Outcome ≥3 self-reported symptoms
Exposure variables aOR (95% CI) p-value
AZT-containing regimens (Y/N) 0.73 (0.35 - 1.52) 0.393
ABC-containing regimens (Y/N) 0.94 (0.53 - 1.67) 0.820
TDF-containing regimens (Y/N) 1.50 (0.71 - 3.21) 0.291
D4T-containing regimens (Y/N) 3.38 (1.19 - 9.60) 0.022*
Age 0.96 (0.85 - 1.09) 0.533
Female gender (Y/N) 1.24 (0.80 - 1.93) 0.343
Rural residence (Y/N) 0.76 (0.47 - 1.29) 0.300
Past-month poor health (Y/N) 2.37 (1.53 - 3.68) <0.001*
Food insecurity (Y/N) 2.03 (0.99 - 4.15) 0.052*
Lack access to basic necessities (Y/N) 1.22 (0.76 - 1.95) 0.405
Antibiotics/TB treatment (Y/N) 1.83 (0.93 - 3.57) 0.079*
Past-week non-adherence (Y/N) 1.16 (0.72 - 1.87) 0.538
≥5 pills/day (Y/N) 1.18 (0.72 - 1.95) 0.513
Daily dosing frequency ≥2 (Y/N) 0.96 (0.59 - 1.57) 0.881
Past-year ARV stock-outs (Y/N) 0.67 (0.59 - 1.57) 0.408
Recent CD4+ <500 cells/µL (Y/N) 1.37 (0.64 - 2.95) 0.415
Recent treatment failure/VL >1 000 copies/mL (Y/N) 0.85 (0.31 - 2.31) 0.748
Any opportunistic infections (Y/N) 4.64 (2.98 - 7.21) <0.001*
Vertical infection (Y/N) 0.76 (0.35 - 1.69) 0.505
Time on treatment 0.98 (0.92 - 1.04) 0.506
NRTI = nucleos(t)ide reverse transcriptase inhibitor; cART = combination antiretroviral therapy; AZT = zidovudine; ABC = abacavir; TDF = tenofovir d4T = stavudine;  
aOR = adjusted odds ratio; CI = confidence interval; Y = yes; N = no; TB = tuberculosis; ARV = antiretroviral; VL = viral load.
*Effects significant at p<0.1.
Table 4. Comparing TDF + FTC + EFV with other EFV-based regimens, all potential covariates simultaneously added to the model (N=468)
Outcome ≥3 self-reported symptoms
Exposure variables aOR (95% CI) p-value
TDF + FTC + EFV (Y/N) 2.67 (1.21 - 5.88) 0.015*
Other EFV-based† cART (Y/N) 1.11 (0.67 - 1.84) 0.694
Age 0.95 (0.85 - 1.06) 0.348
Female gender (Y/N) 1.17 (0.76 - 1.82) 0.479
Rural residence (Y/N) 0.77 (0.46 - 1.32) 0.344
Past-month poor health (Y/N) 2.24 (1.45 - 3.46) <0.001*
Food insecurity (Y/N) 1.85 (0.91 - 3.77) 0.090*
Lack access to basic necessities (Y/N) 1.26 (0.79 - 2.00) 0.340
Antibiotics/TB treatment (Y/N) 1.74 (0.89 - 3.38) 0.106
Past-week non-adherence (Y/N) 1.20 (0.74 - 1.93) 0.457
≥5 pills/day (Y/N) 1.25 (0.76 - 2.04) 0.386
Daily dosing frequency ≥2 (Y/N) 1.08 (0.67 - 1.76) 0.749
Past-year ARV stock-outs (Y/N) 0.72 (0.28 - 1.86) 0.501
Recent CD4+ <500 cells/µL (Y/N) 1.43 (0.66 - 3.07) 0.365
Recent treatment failure/VL >1 000 copies/mL (Y/N) 1.00 (0.37 - 2.71) 0.991
Any opportunistic infections (Y/N) 4.66 (3.01 - 7.22) <0.001*
Vertical infection (Y/N) 0.76 (0.35 - 1.68) 0.499
Time on treatment 0.98 (0.93 - 1.05) 0.599
TDF = tenofovir; FTC = emtricitabine; EFV = efavirenz; aOR = adjusted odds ratio; CI = confidence interval; Y = yes; N = no; cART = combination antiretroviral therapy; TB = tuberculosis; 
ARV = antiretroviral; VL = viral load.
*Effects significant at p<0.1.
†All EFV-containing regimens excluding TDF + FTC + EFV.
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Results
Sociodemographic, health and wellbeing characteristics 
of the study population
Community controls were demographically similar to HIV-positive 
adolescents in many sociodemographic characteristics except for 
age and gender. The controls were significantly older than the 
HIV-positive adolescents, with a median age of 15 (interquartile 
range (IQR) 12 - 17) years v. 13 (IQR 11 - 16) years; p<0.001) and a 
comparatively higher proportion were girls, 60.8% v. 55.1%; p=0.036). 
Of the controls (n=467), 94.0% were Xhosa-speaking, 76.2% were 
urban dwellers, 84.4% lived in formal housing, and 63.6% lacked 
access to basic necessities (results not presented). Compared with 
those included in the study, excluded adolescents were significantly 
younger (median age difference 1 year; p<0.001), and reported higher 
rates of food insecurity (proportional difference 3.9%; p=0.067) and 
higher rates of past-week non-adherence (proportional difference 
Table 5. Comparing PI-based with NNRTI-based regimens, all potential covariates simultaneously added to the model (N=468)
Outcome ≥3 self-reported symptoms
Exposure variables aOR (95% CI) p-value
LPV/r-containing regimens (Y/N) 0.47 (0.21 - 1.04) 0.061*
EFV-containing regimens (Y/N) 0.86 (0.45 - 1.65) 0.651
Age 1.00 (0.90 - 1.11) 0.959
Female gender (Y/N) 1.16 (0.78 - 1.83) 0.465
Rural residence (Y/N) 0.74 (0.43 - 1.25) 0.258
Past-month poor health (Y/N) 2.34 (1.52 - 3.61) <0.001*
Food insecurity (Y/N) 1.95 (0.96 - 3.95) 0.063*
Lack access to basic necessities (Y/N) 0.81 (0.51 - 1.29) 0.375
Antibiotics/TB treatment (Y/N) 1.75 (0.90 - 3.40) 0.100
Past-week non-adherence (Y/N) 1.12 (0.70 - 1.81) 0.634
≥5 pills/day (Y/N) 1.11 (0.71 - 1.75) 0.639
Daily dosing frequency ≥2 (Y/N) 1.13 (0.68 - 1.87) 0.636
Past-year ARV stock-outs (Y/N) 0.69 (0.26 - 1.79) 0.441
Recent CD4+ <500 cells/µL (Y/N) 1.42 (0.67 - 3.04) 0.363
Recent treatment failure/VL >1 000 copies/mL (Y/N) 0.85 (0.32 - 2.23) 0.734
Any opportunistic infections (Y/N) 4.44 (2.87 - 6.86) <0.001*
Vertical infection (Y/N) 0.75 (0.34 - 1.65) 0.473
Time on treatment 0.98 (0.92 - 1.04) 0.487
PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; LPV/r = ritonavir-boosted lopinavir; EFV = efavirenz; aOR = adjusted odds ratio; CI = confidence interval;  
Y = yes; N = no; TB = tuberculosis; ARV = antiretroviral; VL = viral load.
*Effects significant at p<0.1.
Table 6. Associations between EFV-containing regimens and multiple symptoms, all potential covariates simultaneously added to 
the model (N=468)
Outcome ≥3 self-reported symptoms
Exposure variables aOR (95% CI) p-value
D4T + 3TC + EFV (Y/N) 3.26 (1.01 - 10.52) 0.048*
TDF + FTC + EFV (Y/N) 2.86 (1.35 - 6.05) 0.006*
ABC + 3TC + EFV (Y/N) 1.08 (0.64 - 1.82) 0.784
Age 0.94 (0.83 - 1.05) 0.255
Female gender (Y/N) 1.19 (0.77 - 1.85) 0.429
Rural residence (Y/N) 0.78 (0.46 - 1.33) 0.362
Past-month poor health (Y/N) 2.27 (1.47 - 3.51) <0.001*
Food insecurity (Y/N) 1.94 (0.94 - 3.97) 0.071*
Lack access to basic necessities (Y/N) 1.24 (0.77 - 1.98) 0.373
Antibiotics/TB treatment (Y/N) 1.80 (0.92 - 3.54) 0.086*
Past-week non-adherence (Y/N) 1.22 (0.75 - 1.98) 0.424
≥5 pills/day (Y/N) 1.26 (0.76 - 2.10) 0.365
Daily dosing frequency ≥2 (Y/N) 1.06 (0.66 - 1.73) 0.805
Past-year ARV stock-outs (Y/N) 0.69 (0.27 - 1.79) 0.444
Recent CD4+ <500 cells/µL (Y/N) 1.41 (0.65 - 3.04) 0.383
Recent treatment failure/VL >1 000 copies/mL (Y/N) 0.91 (0.33 - 2.50) 0.860
Any opportunistic infections (Y/N) 4.66 (3.00 - 7.25) <0.001*
Vertical infection (Y/N) 0.76 (0.34 - 1.67) 0.491
Time on treatment 0.98 (0.93 - 1.05) 0.582
EFV = efavirenz; D4T = stavudine; 3TC = lamivudine; TDF = tenofovir; FTC = emtricitabine; ABC = abacavir; aOR= adjusted odds ratio; CI = confidence interval; Y = yes; N = no;  
TB = tuberculosis; ARV = antiretroviral; VL = viral load.
*Effects significant at p<0.1.
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13%; p<0.001), but they were not significantly different with regard to any 
other factors tested (Table 1). Of the included HIV-positive adolescents 
(n=501), median age 14 years (IQR 12 - 16), 97.4% were Xhosa speaking, 
80.4% were urban dwellers, 82.4% lived in formal housing, 54.3% were 
girls, 66.5% were vertically infected, 85.2% knew their own HIV status, 
and 67.5% lacked access to basic necessities (Table 2).
Prevalence of cART regimens, multiple symptoms  
and non-adherence
The most common cART regimens were ABC + 3TC + EFV (n=165, 
32.9%) and TDF + FTC + EFV (n=116, 23.2%) (Table 2). For NRTI-
based regimens, the prevalence was 46.1% for ABC-containing, 
28.5% for TDF-containing and 10.2% for AZT-containing regimens, 
7.6% for 3TC-monotherapy, and 6.4% for d4T-containing regimens. 
For NNRTI-based regimens, the prevalence was 70.7% for EFV-
containing and 0.6% for NVP-containing regimens. For PI-based 
regimens, the prevalence was 17.0% for LPV/r-containing regimens. 
Reported symptoms were skin rash (44.5%), diarrhoea (43.7%), 
nausea/vomiting (43.3%), tiredness (42.1%), stomach problems 
(40.3%), dizziness (33.3%), ear problems (31.9%), sleep problems/bad 
dreams (29.7%), weight loss (26.2%) and anxiety (2.4%). The overall 
prevalence of multiple (>3) symptoms was 59.7% (95% CI 55.3 - 63.9) 
and the prevalence of past-week non-adherence was 29.7% (95% 
CI 25.9 - 33.9).
Associations of cART regimens with reports of multiple 
symptoms among adolescents
Independent of covariates, d4T-containing regimens were signi-
ficantly associated with higher odds of reporting multiple symptoms 
(adjusted odds ratio (aOR) 3.38; 95% CI 1.19 - 9.60) compared with 
other NRTI-based regimens (Table 3). Treatment with the FDC 
containing TDF + FTC + EFV was independently associated with 
higher odds of reporting multiple symptoms (aOR 2.67; 95% CI 1.21 - 
5.88) compared with all other EFV-containing regimens combined 
(Table 4). LPV/r-containing regimens were significantly associated 
with lower odds of reporting multiple symptoms compared with 
EFV-containing regimens (aOR 0.47; 95% CI 0.21 - 1.04) (Table 5). 
Considering only EFV-containing regimens, adolescents on d4T + 
3TC + EFV and TDF + FTC + EFV were more likely to report multiple 
symptoms than those on ABC + 3TC + EFV (aOR 3.26; 95% CI 1.01 - 
10.52, aOR 2.86; 95% CI 1.35 - 6.05 and aOR 1.08; 95% CI 0.64 - 
1.82, respectively) (Table 6). When all covariates were held at their 
mean values in marginal-effects models, the predicted probability of 
reporting multiple symptoms was 40.0% for HIV-positive adolescents 
who did not report any of these regimens. For the average adolescent 
on LPV/r-containing regimens, the predicted probability of reporting 
multiple symptoms was 49.0%. With the FDC containing TDF + 
FTC + EFV, the predicted probability of reporting multiple symptoms 
was 76.0%. With d4T-containing regimens, the predicted probability 
of reporting multiple symptoms was 80.0% (Fig. 1).
Associations of cART regimens with reports of past-
week non-adherence among adolescents
Among regimens that were significantly associated with multiple 
symptoms, only the FDC of TDF + FTC + EFV was associated with 
reduced non-adherence (i.e. higher adherence) among adolescents, 
independent of covariates (aOR 0.44; 95% CI 0.21 - 0.93) (Table 8). 
Multiple symptoms were not significantly associated with non-
Table 8. Associations of cART-regimens (only those significantly associated with multiple symptoms) with past-week non-
adherence among ART-initiated adolescents, all potential covariates simultaneously added to the model (N=468)
Outcome: past-week non-adherence
Exposure variables aOR (95% CI) p-value
TDF + FTC + EFV (FDC) regimens (Y/N) 0.44 (0.21 - 0.93) 0.032*
D4T-containing regimens (Y/N) 0.67 (0.28 - 1.63) 0.380
LPV/r-containing regimens (Y/N) 0.80 (0.42 - 1.50) 0.477
Clinic staff problems (Y/N) 1.72 (1.11 - 2.67) 0.015*
Clinic transport problems (Y/N) 1.47 (0.94 - 2.30) 0.090*
Clinic facility problems (Y/N) 1.13 (0.70 - 1.82) 0.612
≥3 medication symptoms (Y/N) 1.15 (0.70 - 1.89) 0.572
Positive status knowledge (Y/N) 1.30 (0.70 - 2.41) 0.399
Age 1.02 (0.90 - 1.16) 0.736
Female gender (Y/N) 0.90 (0.58 - 1.41) 0.648
Rural residence (Y/N) 1.12 (0.66 - 1.90) 0.682
Past-month poor health (Y/N) 0.77 (0.49 - 1.23) 0.271
Food insecurity (Y/N) 2.02 (1.09 - 3.76) 0.027*
Lack access to basic necessities (Y/N) 0.86 (0.53 - 1.40) 0.549
Orphanhood (any) 0.85 (0.54 - 1.35) 0.501
Antibiotics/TB treatment (Y/N) 0.90 (0.48 - 1.67) 0.729
≥5 pills/day (Y/N) 0.71 (0.44 - 1.17) 0.181
Daily dosing frequency ≥2 (Y/N) 1.46 (0.87 - 2.44) 0.153
Past-year ARV stock-outs (Y/N) 2.55 (1.02 - 6.39) 0.045*
Recent CD4+ <500 cells/µL (Y/N) 1.44 (0.72 - 2.88) 0.309
Recent treatment failure/VL >1 000 copies/mL (Y/N) 1.86 (0.79 - 4.38) 0.154
Any opportunistic infections (Y/N) 1.54 (0.94 - 2.50) 0.086*
Vertical infection (Y/N) 0.58 (0.27 - 1.26) 0.169
Time on treatment 1.02 (0.96 - 1.08) 0.604
cART = combination antiretroviral therapy; ART = antiretroviral therapy; TDF = tenofovir; FTC = emtricitabine; EFV = efavirenz; FDC = fixed-dose combination; d4T = stavudine;  
LPV/r = ritonavir-boosted lopinavir; aOR= adjusted odds ratio; CI = confidence interval; Y = yes; N = no; TB = tuberculosis; ARV = antiretroviral; VL = viral load.
*Effects significant at p<0.1.
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adherence in this model (aOR 1.15; 95% CI 0.70 - 1.89). No other 
ART regimens were shown to be significantly associated with non-
adherence in models testing the relationship between all major 
cART and past-week non-adherence in this study (results available 
on request).
Discussion
This study is the first to test associations between cART regimens 
and reports of multiple symptoms among HIV-positive adolescents, 
using a large community-traced sample from SA. These findings have 
several implications for ART programming in sub-Saharan Africa. 
First, HIV-positive ART-experienced adolescents have a large burden 
of multiple symptoms. Nearly two-thirds of the adolescents in our 
study had experienced three or more symptoms in the past 6 months. 
Reports of multiple symptoms were most common in adolescents 
on d4T-based regimens and the FDC containing TDF + FTC + EFV. 
Second, adolescents on LPV/r were protected against most mild 
to moderate symptoms, notably against dizziness (Table 7). These 
results are similar to those of studies in high-income settings.[22,23] In 
this study, the predicted probability of reporting multiple symptoms 
doubled for adolescents on d4T-containing regimens and those on 
the FDC containing TDF + FTC + EFV, and increased by only 9% 
for adolescents on LPV/r-containing regimens compared with those 
who did not report being on any of these regimens. Third, despite 
the unfavourable symptom profile, adolescents on TDF + FTC + 
EFV were the most adherent sub-group by self-report, suggesting that 
multiple symptoms did not have a major influence on non-adherence 
when pill burden and daily dosing frequency were substantially 
reduced. Alternatively, this better adherence may explain why 
adolescents on TDF + FTC + EFV reported many symptoms.
In clinical practice, it is often suggested that the observed 
association between TDF + FTC + EFV and self-reported side-effects 
is mainly due to its EFV component and that the side-effects profile 
of TDF + FTC + EFV may not be different from that of other EFV-
containing regimens, despite its being an FDC. Our findings show 
that adolescents on TDF + FTC + EFV had about 2.5 times higher 
odds of reporting multiple symptoms compared with those on other 
EFV-based regimens. Among EFV-based regimens, adolescents on 
d4T + 3TC + EFV had higher odds of reporting multiple symptoms 
compared with those on TDF + FTC + EFV and ABC + 3TC + EFV 
(in that order of decreasing odds), suggesting that the NRTI backbone 
may play a more important role in cART symptoms profiling than the 
NNRTI component.
Our findings show that adolescents on LPV/r-containing regimens 
reported the least number of symptoms. However, looking at the 
three common LPV/r-containing cART regimens in this study 
(Table  7), the number of symptoms reported by adolescents on 
AZT + 3TC + LPV/r and ABC + AZT + LPV/r was higher than that 
reported by those on ABC + 3TC + LPV/r and comparable to that 
reported by those on d4T + 3TC + EFV. This suggests that when AZT 
is present in an LPV/r-containing regimen, the symptoms profile is 
comparable to that of d4T-based regimens. Our data cannot explain 
the cause of this variation, and we recommend further examination.
Study limitations
This study has notable limitations. First, more than half of the 
interviewed sample (53.0%) was excluded owing to unclear or missing 
information in patient files and participant responses. Our findings 
may therefore have suffered from selection bias. Compared with 
those included, excluded adolescents were significantly younger, and 
more likely to be food insecure and non-adherent to medication. Of 
the excluded sample (n=558), 50.4% did not know their medication 
and what it was for. It is likely that these were adolescents whose 
status had not yet been disclosed to them. It is possible that the 
most vulnerable adolescents were excluded from analysis. Recent 
studies have shown an association between HIV status disclosure 
and increased adherence to ART among adolescents.[5] By excluding 
these adolescents, we have under-reported non-adherence rates in 
this study and this may have attenuated the relationship between 
cART regimens and past-week non-adherence. However, to report 
symptoms associated with ART use, participants had to be on ARVs 
at the time of the study. It is therefore unlikely that these exclusions 
affected the main objective of the study, which was to examine 
the relationship between cART regimens and multiple symptoms. 
Instead, including these adolescents would have confounded this 
relationship, since some of them were defaulters and symptoms 
reported by defaulters were likely to be due to virological activity 
rather than the ARV regimens they were taking. Moreover, analyses 
were based on a sufficiently large sample to enable detection of a true 
effect if one existed (n=501, 47.0% of those included), compared with 
existing studies of ART outcomes in children.[8,17,21]
Second, as this was a community study, we did not conduct 
clinical assessments for ART-related lipodystrophy/lipoatrophy and 
dyslipidaemia commonly associated with d4T and LPV/r treatment. 
We also did not objectively measure AZT-associated anaemia 
and neutropenia or conduct other biochemical/haematological 
assessments. In addition, we excluded reports of headaches (a 
common side-effect associated with AZT use[48]) from analysis because 
of similar rates among HIV-positive participants and community 
controls. It is therefore possible that we have underestimated the 
extent of symptoms associated with cART use in our sample.
Third, our data are cross-sectional and we therefore cannot 
conclude causality from the observed associations, i.e. we cannot 
be certain that the symptoms analysed were indeed caused by the 
medication. Nevertheless, we included a wide range of a priori 
covariates in all logistic regression models to minimise the effects 
of confounding in non-randomised designs. However, this strategy 
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Fig. 1. Marginal-effects model predicting the probability of multiple symptoms 
among HIV-positive adolescents, according to combination antiretroviral 
therapy status. (d4T = stavudine; TDF = tenofovir; FTC = emtricitabine; 
EFV = efavirenz; AZT = zidovudine; ABC = abacavir; LPV/r = lopinavir/
ritonavir; HIV+ = HIV-positive; ART = antiretroviral therapy.)
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could have led to low power and over-adjusted odds ratios. In 
addition, we cannot rule out that regimens with high rates of multiple 
symptoms had these because they also had the highest rates of 
adherence. Similarly, regimens with low adherence may have had 
lower rates of side-effects in the analysis, even though these could 
be the drugs that actually cause the most side-effects when taken as 
prescribed.
Fourth, most outcomes were measured by self-report on past 
events, so recall and social desirability bias could have played a role 
in our findings. Moreover, in an attempt to keep the questionnaire 
brief, some symptoms that are clinically distinct were combined, 
e.g. shingles and skin rash. However, our assumption was that HIV-
positive adolescents in this very resource-limited setting were more 
likely to be knowledgeable about skin rash than shingles (varicella 
zoster), therefore making our findings less likely to be confounded 
by the opportunistic infection.
Fifth, we analysed multiple symptoms (a summation of 10 mild 
to moderate symptoms) as a dichotomous variable to generate two 
groups that could benefit from targeted clinical intervention. For 
instance, those who report less than three symptoms could benefit 
from symptoms counselling, while those who report three or more 
symptoms could be offered counselling and/or regimen modification 
if warranted. However, there is a debate in the literature about the 
statistical effects of categorisation of continuous variables[49-51] and 
methods used in cut-off determination.[52-56]
Sixth, adolescents who only reported broadly that they were 
on an FDC (n=11) were not included in the analysis, because this 
term is neither specific nor unique to ART. For instance, FDC can 
be used in reference to TB medication or various duo/triple ART 
co-formulations such as rifampicin + isoniazid (TB medication), or 
ABC + 3TC and AZT + 3TC (dual ART combination pills). However, 
according to the 2015 South African national ART guidelines,[6] 
this term was often used in reference to TDF + FTC + EFV, and the 
prevalence of TDF + FTC + EFV use in the full sample is therefore 
likely to be larger than reported.
Despite these many limitations, this study is unique in that it is 
the first to use a large community-traced sample of HIV-positive 
adolescents enrolled on national ART programmes, thus providing 
preliminary evidence from real-world resource-constrained settings. 
Findings from a community-based sample have better external 
validity than those from a clinic-based sample. While these findings 
should be tested in other settings within and outside SA to check 
reproducibility, with randomised and longitudinal study designs 
to test causality, the study population and setting are reasonably 
representative of other low-resource settings in sub-Saharan Africa.
Conclusions
In our sample of 10 - 19-year-old HIV-positive ART-experienced 
SA adolescents, rates of multiple symptoms were high. Our findings 
support the WHO-recommended discontinuation of d4T use. ART 
provision should be accompanied by counselling on symptoms as 
part of routine HIV management. Simplified regimens have the 
potential to increase adherence among adolescents, so more one-
pill-a-day FDC ARVs are urgently needed. Our findings underscore 
the dilemma faced by clinicians when choosing between low-toxicity 
regimens and those that promote ART adherence, and can contribute 
to informing age- and context-appropriate treatment guidelines. It 
is important for these findings to be tested in future longitudinal 
or randomised designs that measure clinical staging, VL, CD4+ 
count and health symptoms prior to cART initiation and outcome 
assessment.
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